Tigecycline displays In Vivo bactericidal activity against extended-spectrum-β-lactamase-producing Enterobacteriaceae after 72-hour exposure period

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 640-642

  Tessier, Pamela R ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; TIGECYCLINE;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DILUTION; ESCHERICHIA COLI; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BETA-LACTAMASES; COLONY COUNT, MICROBIAL; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; GENE EXPRESSION; KLEBSIELLA PNEUMONIAE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; THIGH; TIME FACTORS;

EID: 84872036620     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01824-12     Document Type: Article

References (9)

1. Agwuh KN, MacGowan A. 2006. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J. Antimicrob. Chemother. 58:256-265.
2. Nicasio AM, Crandon JL, Nicolau DP. 2009. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother. 53:2756-2761.
3. Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Bhavnani SM, Ellis-Grosse E. 2009. Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn. Microbiol. Infect. Dis. 63:155-159.
4. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. 2005. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 49:220-229.
5. Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG. 2007. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob. Agents Chemother. 51 :1939-1945.
6. Crandon JL, Banevicius MA, Nicolau DP. 2009. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob. Agents Chemother. 53:1165-1169.
7. Maglio DM, Captiano B, Banevicius MA, Tessier PA, Nightingale CH, Nicolau DP. 2004. Efficacy of clarithromycin against Streptococcus pneumoniae expressing mef(A)-mediated resistance. Int. J. Antimicrob. Agents 23:498-501.
8. Tessier PR, Keel RA, Hagihara M, Crandon JL, Nicolau DP. 2012. Comparative in vivo efficacy of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob. Agents Chemother. 56:2342-2346.
9. Keel RA, Tessier PR, Crandon JL, Nicolau DP. 2012. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrob. Agents Chemother. 56:4403-4407.